Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia

Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735

Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification

Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells

Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675

Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia

Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

Miller, J. S., Soignier, Y., Panoskaltsis‐Mortari, A., McNearney, S. A., Yun, G. H., Fautsch, S. K., McKenna, D. H., Le, C. T., DeFor, T. E., Burns, L. J., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2974 · Cited by 1,894

Exploiting autophagy balance in T and NK cells as a new strategy to implement adoptive cell therapies

Giansanti, M., Theinert, T., Boeing, S. K., Haas, D., Schlegel, P., Vacca, P., Nazio, F., & Caruana, I. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01893-w · Cited by 24

Biomimetic Bacterial Capsule for Enhanced Aptamer Display and Cell Recognition

Wang, X., Jia, B., Lee, K., Davis, B., Wen, C., Wang, Y., Zheng, H., & Wang, Y. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c11208 · Cited by 22

The Role of Chemokines in Orchestrating the Immune Response to Pancreatic Ductal Adenocarcinoma

Lekan, A. A., & Weiner, L. M. (2024) · Cancers · doi:10.3390/cancers16030559 · Cited by 24

Pediatric Solid Cancers: Dissecting the Tumor Microenvironment to Improve the Results of Clinical Immunotherapy

Belgiovine, C., Mebelli, K., Raffaele, A., Cicco, M. D., Rotella, J., Pedrazzoli, P., Zecca, M., Riccipetitoni, G., & Comoli, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063225 · Cited by 22

Global research trends in CAR-T cell therapy for solid tumors: A comprehensive visualization and bibliometric study (2012–2023)

Miao, L., Zhang, J., Xu, W., Qian, Q., Zhang, G., Yuan, Q., Lv, Y., Zhang, H., Shen, C., & Wang, W. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2338984 · Cited by 22

The future of immunotherapy for diffuse large B‐cell lymphoma

Duell, J., & Westin, J. R. (2024) · International Journal of Cancer · doi:10.1002/ijc.35156 · Cited by 22

Advances in preclinical and clinical studies of oncolytic virus combination therapy

Du, W., Na, J., Zhong, L., & Zhang, P. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1545542 · Cited by 24

The Cancer-Immunity Cycle in Multiple Myeloma

Casey, M., & Nakamura, K. (2021) · ImmunoTargets and Therapy · doi:10.2147/itt.s305432 · Cited by 24

Empowering pancreatic tumor homing with augmented anti-tumor potency of CXCR2-tethered CAR-NK cells

Yoon, J. H., Yoon, H., Kang, H. J., Yoo, H., Choi, M. J., Chung, J.-Y., Seo, M., Kim, M., Lim, S. O., Kim, Y. J., et al. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200777 · Cited by 21

BET inhibitors drive Natural Killer activation in non-small cell lung cancer via BRD4 and SMAD3

Reggiani, F., Talarico, G., Gobbi, G., Sauta, E., Torricelli, F., Manicardi, V., Zanetti, E., Orecchioni, S., Falvo, P., Piana, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46778-8 · Cited by 21

Functional genomics identifies N-acetyllactosamine extension of complex N-glycans as a mechanism to evade lysis by natural killer cells

Zhuang, X., Woods, J., Ji, Y., Scheich, S., Mo, F., Rajagopalan, S., Coulibaly, Z. A., Voß, M., Urlaub, H., Staudt, L. M., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114105 · Cited by 22

Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma

Pu, J., Liu, T., Sharma, A., Jiang, L., Wei, F., Ren, X., Schmidt‐Wolf, I. G. H., & Hou, J. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00576-6 · Cited by 23

Anti-Mesothelin CAR-NK cells as a novel targeted therapy against cervical cancer

Kutle, I., Polten, R., Stalp, J. L., Hachenberg, J., Todzey, F., Hass, R., Zimmermann, K., von der Ohe, J., von Kaisenberg, C., Neubert, L., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1485461 · Cited by 24

CAR-NK cell therapy: a potential antiviral platform.

Lin, M.-H., Hu, L.-J., Miller, J. S., Huang, X.-J., & Zhao, X.-Y. (2025) · Science Bulletin · doi:10.1016/j.scib.2025.01.002 · Cited by 21

Virus-free CRISPR knockin of a chimeric antigen receptor into KLRC1 generates potent GD2-specific natural killer cells

Shankar, K., Zingler-Hoslet, I., Tabima, D. M., Zima, S. R. T., Shi, L., Gimse, K., Forsberg, M. H., Katta, V., Davis, S. Z., Maldonado, D., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.01.024 · Cited by 23

Generation of an NFκB-Driven Alpharetroviral “All-in-One” Vector Construct as a Potent Tool for CAR NK Cell Therapy

Rudek, L. S., Zimmermann, K., Galla, M., Meyer, J., Kuehle, J., Σταμοπούλου, Α., Brand, D., Sandalcioglu, I. E., Neyazi, B., Thomas, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.751138 · Cited by 22

CAR-NK Cells for Cancer Therapy: Molecular Redesign of the Innate Antineoplastic Response

Rojas‐Martínez, A., Cienfuegos-Jiménez, O., & Vázquez‐Garza, E. (2021) · Current Gene Therapy · doi:10.2174/1566523222666211217091724 · Cited by 21

Advancements of Common Gamma-Chain Family Cytokines in Cancer Immunotherapy

Wolfarth, A. A., Dhar, S., Goon, J. B., Ezeanya, U. I., Ferrando‐Martínez, S., & Lee, B. H. (2022) · Immune Network · doi:10.4110/in.2022.22.e5 · Cited by 21

Lateral plate mesoderm cell-based organoid system for NK cell regeneration from human pluripotent stem cells

Huang, D., Li, J., Hu, F., Weng, Q., Weng, Q., Peng, H., Wu, B., Xia, C., Wu, H., Xiong, J., et al. (2022) · Cell Discovery · doi:10.1038/s41421-022-00467-2 · Cited by 21

Natural killer cells for antiviral therapy

Smith, D. M., Schafer, J. R., Tullius, B. P., Witkam, L., & Paust, S. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abl5278 · Cited by 22

A costimulatory chimeric antigen receptor targeting TROP2 enhances the cytotoxicity of NK cells expressing a T cell receptor reactive to human papillomavirus type 16 E7

Poorebrahim, M., Quiros‐Fernandez, I., Marmé, F., Burdach, S. E. G., & Cid-Arregui, Á. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216242 · Cited by 21

Natural killer cell therapy targeting cancer stem cells: Old wine in a new bottle

Guo, F., Zhang, Y., Bai, L., & Cui, J. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216328 · Cited by 21

Preclinical assessment of CAR-NK cell-mediated killing efficacy and pharmacokinetics in a rapid zebrafish xenograft model of metastatic breast cancer

Shankar, N. M., Ortíz-Montero, P., Kurzyukova, A., Rackwitz, W., Künzel, S. R., Wels, W. S., Tonn, T., Knopf, F., & Eitler, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1254821 · Cited by 21

Enhancing cord blood stem cell-derived NK cell growth and differentiation through hyperosmosis

Wen, W., Chen, X., Shen, X., Li, H.-Y., Zhang, F., Fang, F., & Zhang, X. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03461-x · Cited by 21

Engineering bionic T cells: signal 1, signal 2, signal 3, reprogramming and the removal of inhibitory mechanisms

Etxeberría, I., Olivera, I., Bolaños, E., Cirella, A., Teijeira, Á., Berraondo, P., & Melero, I. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0464-1 · Cited by 23

Genetic and epigenetic modification of human primary NK cells for enhanced antitumor activity

Kararoudi, M. N., Tullius, B. P., Chakravarti, N., Pomeroy, E. J., Moriarity, B. S., Béland, K., Colamartino, A., Haddad, É., Chu, Y., Cairo, M. S., et al. (2020) · Seminars in Hematology · doi:10.1053/j.seminhematol.2020.11.006 · Cited by 23

Next-Generation Immunotherapies to Improve Anticancer Immunity

Shi, Y., Tomczak, K. J., Li, J., Ochieng, J. K., Lee, Y., & Haymaker, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.566401 · Cited by 22

State-of-Art of Cellular Therapy for Acute Leukemia

Lee, J. B., Vasić, D., Kang, H., Fang, K., & Li, Z. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094590 · Cited by 22

Pediatric Tumors-Mediated Inhibitory Effect on NK Cells: The Case of Neuroblastoma and Wilms’ Tumors

Pelosi, A., Fiore, P. F., Matteo, S. D., Veneziani, I., Caruana, I., Ebert, S., Munari, E., Moretta, L., Maggi, E., & Azzarone, B. G. (2021) · Cancers · doi:10.3390/cancers13102374 · Cited by 21

NK Cell-Based Immunotherapy and Therapeutic Perspective in Gliomas

Pan, C., Zhai, Y., Li, G., Jiang, T., & Zhang, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.751183 · Cited by 23

Mechanisms of resistance to T cell‐based immunotherapy in head and neck cancer

Lee, M. Y., & Allen, C. T. (2020) · Head & Neck · doi:10.1002/hed.26158 · Cited by 21

In vivo gene editing and in situ generation of chimeric antigen receptor cells for next-generation cancer immunotherapy

Zhang, W., & Huang, X. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01633-7 · Cited by 20

Revolutionising Cancer Immunotherapy: Advancements and Prospects in Non‐Viral CAR ‐ NK Cell Engineering

Zhou, Z., Chen, Y., Ba, Y., Xu, H., Zuo, A., Liu, S., Zhang, Y., Weng, S., Ren, Y., Luo, P., et al. (2024) · Cell Proliferation · doi:10.1111/cpr.13791 · Cited by 20

Genetically modified CD19-targeting IL-15 secreting NK cells for the treatment of systemic lupus erythematosus

Fu, Y., Xu, Z., Wu, C., Gao, F., Huang, P., Jiang, F., Hu, C., Patsoukis, N., Wang, Y., Cui, Z., et al. (2025) · Annals of the Rheumatic Diseases · doi:10.1016/j.ard.2025.07.028 · Cited by 20

Selective HLA knockdown and PD-L1 expression prevent allogeneic CAR-NK cell rejection and enhance safety and anti-tumor responses in xenograft mice

Liu, F., Tarannum, M., Zhao, Y., Zhang, Y. J., Ham, J. D., Lei, K., Qiang, Y., Deng, X., Nguyen, M., Dinh, K., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63863-8 · Cited by 23

Hybrid Nanocarriers for Cancer Therapy: Advancements in Co-Delivery of Gene Therapy and Immunotherapy

Berikkhanova, K., Inuwa, I., Jibo, A. G., Berikkhanov, N., Bikhanov, N., Sultan, Y., & Omarbekov, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010248 · Cited by 24

Heat Shock Proteins in Lymphoma Immunotherapy

Albakova, Z., Mangasarova, Y., & Sapozhnikov, A. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.660085 · Cited by 22

Transient blockade of TBK1/IKKε allows efficient transduction of primary human natural killer cells with vesicular stomatitis virus G-pseudotyped lentiviral vectors

Chockley, P. J., Patil, S. L., & Gottschalk, S. M. (2021) · Cytotherapy · doi:10.1016/j.jcyt.2021.04.010 · Cited by 22

The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers

Herrera, L., Santos, S. D. M., Vesga, M. Á., Carrascosa, T., García‐Ruiz, J. C., Pérez‐Martínez, A., Juan, M., & Eguizábal, C. (2021) · Cancers · doi:10.3390/cancers13215418 · Cited by 20

Human induced-T-to-natural killer cells have potent anti-tumour activities

Jiang, Z., Qin, L., Tang, Y., Liao, R. J., Shi, J., He, B., Li, S., Zheng, D., Cui, Y., Wu, Q., et al. (2022) · Biomarker Research · doi:10.1186/s40364-022-00358-4 · Cited by 20

Natural Killer Cells: A Promising Kit in the Adoptive Cell Therapy Toolbox

Xiao, J., Zhang, T., Gao, F., Zhou, Z., Shu, G., Zou, Y., & Yin, G. (2022) · Cancers · doi:10.3390/cancers14225657 · Cited by 19

Using natural killer cell‐derived exosomes as a cell‐free therapy for leukemia

Samara, A., Anbar, M., Shapira, S., Zemlyansky, A., Zozovsky, A., Raanani, P., Granot, G., & Rozovski, U. (2022) · Hematological Oncology · doi:10.1002/hon.3111 · Cited by 20

Chimeric antigen receptor T-cell therapy for multiple myeloma

Wang, Z., Chen, C., Wang, L., Jia, Y., & Qin, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1050522 · Cited by 21

Preclinical scenario of targeting myocardial fibrosis with chimeric antigen receptor (CAR) immunotherapy

Ferrer‐Curriu, G., Soler‐Botija, C., Charvátová, S., Motais, B., Roura, S., Gálvez‐Montón, C., Tortajada, M., Egea, O. I., Emdin, M., Lupón, J., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114061 · Cited by 22

Generation and Functional Characterization of Anti-CD19 Chimeric Antigen Receptor-Natural Killer Cells from Human Induced Pluripotent Stem Cells

Klaihmon, P., Kang, X., Issaragrisil, S., & Luanpitpong, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310508 · Cited by 20

Optimized conditions for gene transduction into primary immune cells using viral vectors

Kim, Y., Lee, D. Y., Choi, J. U., Park, J. S., Lee, S. M., Kang, C. H., & Park, C. H. (2023) · Scientific Reports · doi:10.1038/s41598-023-39597-2 · Cited by 20

Genetic and Molecular Basis of Heterogeneous NK Cell Responses against Acute Leukemia

Makanga, D. R., de Lorenzo, F. D. R., David, G., Willem, C., Dubreuil, L., Legrand, N., Guillaume, T., Péterlin, P., Lebourgeois, A., Béné, M. C., et al. (2020) · Cancers · doi:10.3390/cancers12071927 · Cited by 20

Overhauling CAR T Cells to Improve Efficacy, Safety and Cost

Chicaybam, L., Bonamino, M., Invitti, A. L., Rozenchan, P. B., Vieira, I. D. L., & Strauss, B. E. (2020) · Cancers · doi:10.3390/cancers12092360 · Cited by 20

C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomas

Jacobson, C. A., & Maus, M. V. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020003391 · Cited by 20

CD19 CAR T cells for B cell malignancies: a systematic review and meta-analysis focused on clinical impacts of CAR structural domains, manufacturing conditions, cellular product, doses, patient’s age, and tumor types

Montagna, E., de Campos, N. S. P., Porto, V. A., da Silva, G. C. P., & Suarez, E. R. (2024) · BMC Cancer · doi:10.1186/s12885-024-12651-6 · Cited by 19

Unraveling the future of genomics: CRISPR, single-cell omics, and the applications in cancer and immunology

Menon, A. V., Song, B., Chao, L., Sriram, D., Chansky, P. A., Bakshi, I., Ulianova, J., & Li, W. (2025) · Frontiers in Genome Editing · doi:10.3389/fgeed.2025.1565387 · Cited by 21

From Multi‐Omics to Visualization and Beyond: Bridging Micro and Macro Insights in CAR‐T Cell Therapy

Gong, Y., Fei, P., Zhang, Y., Xu, Y., & Wei, J. (2025) · Advanced Science · doi:10.1002/advs.202501095 · Cited by 25

Technologies for chimeric antigen receptor transgene delivery

Xiao, Y., Wu, B., Zhou, Q., Wu, F., Li, N., Xu, C., & Han, X. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.05.011 · Cited by 21

Cytokine Engineering in CAR-T Cell Therapy: Next-Generation Strategies

Kim, S., Heo, S. H., 백효진, & Hwang, S. S. (2025) · Immune Network · doi:10.4110/in.2025.25.e43 · Cited by 21

Humanized Mouse Models for the Advancement of Innate Lymphoid Cell-Based Cancer Immunotherapies

Horowitz, N. B., Mohammad, I., Moreno‐Nieves, U. Y., Koliesnik, I. O., Tran, Q., & Sunwoo, J. B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.648580 · Cited by 19

Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives

Kwok, M., Agathanggelou, A., Davies, N., & Stanković, T. (2021) · Cancers · doi:10.3390/cancers13184681 · Cited by 20

Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell Malignancies

Polgárová, K., Otáhal, P., Šálek, C., & Pytlík, R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.876758 · Cited by 19

Recent advances in biomaterial-assisted cell therapy

Chen, Y., Pal, S., & Hu, Q. (2022) · Journal of Materials Chemistry B · doi:10.1039/d2tb00583b · Cited by 20

Learning to Be Elite: Lessons From HIV-1 Controllers and Animal Models on Trained Innate Immunity and Virus Suppression

Sugawara, S. K., Reeves, R. K., & Jost, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.858383 · Cited by 23

Learning from TCR Signaling and Immunological Synapse Assembly to Build New Chimeric Antigen Receptors (CARs)

Cassioli, C., Patrussi, L., Valitutti, S., & Baldari, C. T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214255 · Cited by 20

Multiplexed engineering and precision gene editing in cellular immunotherapy

Biederstädt, A., Manzar, G. S., & Daher, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1063303 · Cited by 19

Prospects for NK-based immunotherapy of chronic HBV infection

Jin, X., & Bi, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1084109 · Cited by 20

Adoptive Cell Therapy for T-Cell Malignancies

Fang, K., Lee, J. B., & Li, Z. (2022) · Cancers · doi:10.3390/cancers15010094 · Cited by 20

Progress in the application of hydrogels in immunotherapy of gastrointestinal tumors

Zheng, H., Li, M., Wu, L., Liu, W., Liu, Y., Gao, J., & Lu, Z. (2023) · Drug Delivery · doi:10.1080/10717544.2022.2161670 · Cited by 20

Addressing Natural Killer Cell Dysfunction and Plasticity in Cell-Based Cancer Therapeutics

Coyle, K. M., Hawke, L. G., & Ormiston, M. L. (2023) · Cancers · doi:10.3390/cancers15061743 · Cited by 19

Good manufacturing practice production of CD34+ progenitor-derived NK cells for adoptive immunotherapy in acute myeloid leukemia

de Jonge, P. K. J. D., van Hauten, P. M. M., Janssen, L. D., de Goede, A. L., Berrien-Elliott, M. M., der Meer, J. M. R. V., Mousset, C. M., Roeven, M. W. H., Foster, M., Blijlevens, N. M. A., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03492-6 · Cited by 19

Harnessing natural killer cell effector function against cancer

Blunt, M. D., & Khakoo, S. I. (2023) · Immunotherapy Advances · doi:10.1093/immadv/ltad031 · Cited by 20

Dual Targeting of Glioblastoma Cells with Bispecific Killer Cell Engagers Directed to EGFR and ErbB2 (HER2) Facilitates Effective Elimination by NKG2D-CAR-Engineered NK Cells

Kiefer, A., Prüfer, M., Röder, J., Serrahima, J. P., Bodden, M., Kühnel, I., Oberoi, P., & Wels, W. (2024) · Cells · doi:10.3390/cells13030246 · Cited by 17

Beyond CAR T cells: exploring alternative cell sources for CAR-like cellular therapies

Tsiverioti, C. A., Gottschlich, A., Trefny, M. P., Theurich, S., Anders, H., Kroiß, M., & Kobold, S. (2024) · Biological Chemistry · doi:10.1515/hsz-2023-0317 · Cited by 20

Natural killer cell engineering – a new hope for cancer immunotherapy

Lin, C., Gobius, I., & Souza-Fonseca-Guimarães, F. (2020) · Seminars in Hematology · doi:10.1053/j.seminhematol.2020.10.002 · Cited by 19

Bone marrow infiltrated natural killer cells predicted the anti-leukemia activity of MCL1 or BCL2 inhibitors in acute myeloid leukemia

Dai, Y., He, S., Hu, F., Li, X., Zhang, J., Chen, S., Zhang, W., Sun, H., & Wang, D. (2021) · Molecular Cancer · doi:10.1186/s12943-020-01302-6 · Cited by 18

Clonal Evolution of High-Risk Chronic Lymphocytic Leukemia: A Contemporary Perspective

Kwok, M., & Wu, C. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.790004 · Cited by 20

CD33 Delineates Two Functionally Distinct NK Cell Populations Divergent in Cytokine Production and Antibody-Mediated Cellular Cytotoxicity

Hejazi, M., Zhang, C., Bennstein, S. B., Balz, V., Reusing, S. B., Quadflieg, M., Hoerster, K., Heinrichs, S., Hanenberg, H., Oberbeck, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.798087 · Cited by 19

Precision sniper for solid tumors: CAR-NK cell therapy

Li, S., Jing, J., Chen, Y., Chi, E., Wang, B., Xie, Z., Yang, W., Shen, H., & Pan, J. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04106-z · Cited by 19

Programmable Smart CAR-T design: A new paradigm in precision immunotherapy driven by logic gates, conditional activation, allogeneic strategies, and artificial intelligence

Wen, P., Ai, Q., Fan, X., Gu, Z., 陈波, & Qian, H. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218257 · Cited by 20

Noninvasive Tracking of Natural Killer Cells Using Gold Nanoparticles

Shamalov, K., Meir, R., Motiei, M., Popovtzer, R., & Cohen, C. J. (2021) · ACS Omega · doi:10.1021/acsomega.1c02143 · Cited by 19

Neoantigen-Reactive T Cells: The Driving Force behind Successful Melanoma Immunotherapy

Davis, L., Tarduno, A., & Lu, Y. (2021) · Cancers · doi:10.3390/cancers13236061 · Cited by 18

Expanded natural killer cells potentiate the antimyeloma activity of daratumumab, lenalidomide, and dexamethasone in a myeloma xenograft model

Thangaraj, J. L., Jung, S., Vo, M.-C., Chu, T.-H., Phan, M. T., Lee, K., Ahn, S., Kim, M., Song, G., Ahn, J., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03322-1 · Cited by 18

A synthetic biology approach to engineering circuits in immune cells

Hoces, D., Blanco, J. M., & Hernández-López, R. A. (2023) · Immunological Reviews · doi:10.1111/imr.13244 · Cited by 19

Navigating chimeric antigen receptor-engineered natural killer cells as drug carriers via three-dimensional mapping of the tumor microenvironment

Huang, S., Xing, F., Dai, Y., Zhang, Z., Zhou, G., Yang, S., Liu, Y., Yuan, Z., Luo, K. Q., Ying, T., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.007 · Cited by 18

“Hurdles race for CAR T ‐cell therapy in digestive tract cancer”

Kronig, M.-N., Wehrli, M., Salas‐Benito, D., & Maus, M. V. (2023) · Immunological Reviews · doi:10.1111/imr.13273 · Cited by 20

Current Situation and Prospect of Adoptive Cellular Immunotherapy for Malignancies

Zhao, D. H., Zhu, D., Cai, F., Jiang, M., Liu, X., Li, T., & Zheng, Z. (2023) · Technology in Cancer Research & Treatment · doi:10.1177/15330338231204198 · Cited by 19

Interleukin-2 is required for NKp30-dependent NK cell cytotoxicity by preferentially regulating NKp30 expression

Kim, N., Yi, E., Lee, E., Park, H. J., & Kim, H. S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1388018 · Cited by 18

Targeting the tumor microenvironment for treating double-refractory chronic lymphocytic leukemia

Lewis, R. I., Stein, A. F. V., & Hallek, M. J. (2024) · Blood · doi:10.1182/blood.2023022861 · Cited by 17

Allogeneic chimeric antigen receptor T cells for children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia

Locatelli, F., Bufalo, F. D., & Quintarelli, C. (2024) · Haematologica · doi:10.3324/haematol.2023.284604 · Cited by 19

Beyond CAR-T: The rise of CAR-NK cell therapy in asthma immunotherapy

Taheri, M. M., Javan, F., Poudineh, M., & Athari, S. S. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05534-8 · Cited by 21

Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia

Sedloev, D. N., Chen, Q., Unglaub, J. M., Schanda, N., Hao, Y., Besiridou, E., Neuber, B., Schmitt, A., Raffel, S., Liu, Y., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01604-y · Cited by 18

Improving CAR T-cells: The next generation

Marple, A., Bonifant, C. L., & Shah, N. N. (2020) · Seminars in Hematology · doi:10.1053/j.seminhematol.2020.07.002 · Cited by 18

Neurotoxicity Biology and Management

Danish, H. H., & Santomasso, B. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000507 · Cited by 18

Toxicities associated with adoptive cellular therapies

Hansen, D. K., Dam, M., & Faramand, R. G. (2021) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2021.101287 · Cited by 18

Novel Immune Cell-Based Therapies to Eradicate High-Risk Acute Myeloid Leukemia

Limongello, R., Marra, A., Mancusi, A., Bonato, S., Hoxha, E., Ruggeri, L., Hui, S. K., Velardi, A., & Pierini, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.695051 · Cited by 21

KIR3DS1 directs NK cell–mediated protection against human adenovirus infections

Jung, J. M., Ching, W., Baumdick, M. E., Hofmann-Sieber, H., Bosse, J. B., Koyro, T., Möller, K. J., Wegner, L. H. M., Niehrs, A., Russu, K., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abe2942 · Cited by 18

Delivery strategies for cell-based therapies in the brain: overcoming multiple barriers

Turk, O. M., Woodall, R. T., Gutova, M., Brown, C. E., Rockne, R. C., & Munson, J. M. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01079-1 · Cited by 18

Novel treatments in B cell non-Hodgkin’s lymphomas

Sawalha, Y., & Maddocks, K. J. (2022) · BMJ · doi:10.1136/bmj-2020-063439 · Cited by 19

Enhanced stimulation of antigen‐specific immune responses against nucleophosmin 1 mutated acute myeloid leukaemia by an anti‐programmed death 1 antibody

Greiner, J., Goetz, M., Schuler, P. J., Bulach, C., Hofmann, S., Schrezenmeier, H., Döhner, H., Schneider, V., & Guinn, B. (2022) · British Journal of Haematology · doi:10.1111/bjh.18326 · Cited by 18

Natural Killer Cells in Chronic Lymphocytic Leukemia: Functional Impairment and Therapeutic Potential

Yano, M., Byrd, J. C., & Muthusamy, N. (2022) · Cancers · doi:10.3390/cancers14235787 · Cited by 18

Design considerations for phase I/II dose finding clinical trials in Immuno-oncology and cell therapy

Liu, R., Lin, J., & Li, P. (2020) · Contemporary Clinical Trials · doi:10.1016/j.cct.2020.106083 · Cited by 18

Current state and perspectives of CAR T cell therapy in central nervous system diseases

Pfeffer, L. K., Fischbach, F., Heesen, C., & Friese, M. A. (2024) · Brain · doi:10.1093/brain/awae362 · Cited by 19

CAR Beyond αβ T Cells: Unleashing NK Cells, Macrophages, and γδ T Lymphocytes Against Solid Tumors

Xian, Y., & Wen, L. (2025) · Vaccines · doi:10.3390/vaccines13060654 · Cited by 19

Targeting cancer stem cells with CAR-based immunotherapy: biology, evidence, and future directions

Hadiloo, K., Mostanadi, P., Asadzadeh, A., Taremi, S., & Esmaeilzadeh, A. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03846-3 · Cited by 19

Abstract 2907: Development of a CAR-NK cellular platform for cancer immunotherapy

Gregoli, K. D., Mode, R., Mitchell, K., Lopez, D. C., de Munnik, S., McLaughlin, R. J., Moiset, G., Brackenbury, L., Schewitz‐Bowers, L. P., & Nunan, R. (2023) · Cancer Research · doi:10.1158/1538-7445.am2023-2907

Safety and Feasibility of a 41BB Co-Stimulated CD19 CAR-NK Cell Therapy in Refractory/Relapsed Large B-Cell Lymphoma

Qian, W., Lei, W., Liu, H., Chen, W., Liang, Y., Sun, Y. E., Tong, X., & Liang, A. (2024) · Blood · doi:10.1182/blood-2024-202988 · Cited by 5

The Efficacy and Safety of CD-19 Directed CAR-NK Therapy in Adults with B-Cell Malignancies: A Meta-Analysis

Carfagnini, C. L., Singh, R., Bechara, S. B., & Kandula, M. (2024) · Blood · doi:10.1182/blood-2024-212016 · Cited by 4

ENHANCED ANTI-TUMOR ACTIVITY OF CD19.CAR-NK CELLS BY INCORPORATING IL-27

Biggi, A., Silvestre, R., Azevedo, J., Tirapelle, M., Malmegrim, K. C. R., Figueiredo, M., Covas, D. T., & Picanço‐Castro, V. (2023) · Hematology Transfusion and Cell Therapy · doi:10.1016/j.htct.2023.09.983 · Cited by 1

Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial

Lei, W., Liu, H., Deng, W., Chen, W., Liang, Y., Gao, W., Yuan, X., Guo, S., Li, P., Wang, J., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-00940-3 · Cited by 78